New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...

Biogen shared plans Monday to buy Pfizer’s experimental neurology drug in a deal worth up to $590 million, reports Reuters. Here are four things to know about the deal. 1. Pfizer is developing the ...

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough ...

Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form ...

(Reuters) - Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer's drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new lawsuit against Biogen Inc ...